Skip to main content

iwCLL 2023 Main banner

iwCLL X / Twitter

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Rogier Mous, MD, PhD

Department of Hematology, UMC Utrecht Cancer Center, Netherlands

N/A

Poster(s):

1135 - Predictive modeling of treatment outcomes in chronic lymphocytic leukemia based on functional profiles at baseline
3008 - An ongoing first-in-human phase 1 trial of NX-5948, an oral Bruton’s tyrosine kinase (BTK) degrader, in patients with relapsed/refractory B cell malignancies, including chronic lymphocytic leukemia (CLL)